The DEDALUS trial is a phase 2, open-label, multicenter study enrolling patients who are eligible for sequential chemo-radiation therapy (CRT) plus immunotherapy.<h4>Methods</h4>Patients had unresectable stage IIIA-C NSCLC, regardless of PD-L1 status. The gene discussed is CD274; the disease is non-small cell lung carcinoma.